基于设备治疗心力衰竭的进展:从临床试验中得到的证据
Ying Wu1, Meiyan Song1, Meifang Wu1
1Department of Cardiology, Affiliated Hospital of Putian University, School of Clinical Medicine, Fujian Medical University, Putian, China.
ESC heart failure
|November 21, 2023
概括
基于设备的疗法对心力衰竭有保存在喷射分数 (HFpEF) 的治疗有希望,提供了超越药物治疗的新治疗选择. 这些创新设备可能会改善患者的生活质量并减少住院治疗.
科学领域:
- 心脏病学 心脏病学
- 生物医学工程 生物医学工程
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭是一种复杂的综合征,由于衰老和并发症,其发病率正在上升.
- 药物治疗选择有限,再住院率高,影响患者的治疗结果和医疗保健成本.
- HFpEF具有异质的表型,需要个性化治疗方法.
研究的目的:
- 审查基于HFpEF的设备治疗的机制和临床证据.
- 探索这些设备如何补充现有的药物疗法.
- 增强管理HFpEF的治疗策略.
主要方法:
- 对HFpEF的基于设备的治疗方法的当前科学文献的审查.
- 对各种器械的作用机制的分析,包括心房间间的分流,神经剥离和节奏.
- 评估关于症状改善,生活质量和心力衰竭再入院减少的临床证据.
主要成果:
- 基于设备的疗法在特定的HFpEF表型中显示出作为药物治疗的辅助剂的潜力.
- 诸如心房间间的分流和迷走神经刺激等干预措施在减少左心室填充压力和自主失衡方面表现有前途.
- 植入式监视器和心脏收缩度调制为管理尿路和心脏功能提供了新的方法.
结论:
- 基于设备的疗法在管理HFpEF方面是一个有前途的前沿.
- 这些创新的治疗方法可以改善HFpEF患者的生活质量并减少住院时间.
- 这些设备的进一步研究和临床整合对于优化HFpEF护理至关重要.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:22Heart Failure Drugs: Diuretics
398
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
398
01:22Heart Failure Drugs: β-Blockers
344
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
344
01:26Heart Failure Drugs: Inotropic Agents
596
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
596
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
171
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
171